Dextromethorphan and guaifenesin use must be monitored cautiously in clients with "weak metabolizer" CYP2D6 enzyme stages and sufferers who're sedated. This combination medication contains a large median poisonous dose (TD50) to median efficient dose (ED50) ratio (or therapeutic index) in these clients.For anyone who is taking this solution on a

Article Under Review